Potent P2Y 12 inhibitors in low-risk patients: Is there a medical need?

Journal of the American College of Cardiology

Volumn 67, Issue 6, 2016, Pages 614-617

  Silvain, Johanne ^a   Kerneis, Mathieu ^a   Montalescot, Gilles ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

acute coronary syndrome; coronary artery disease; percutaneous coronary intervention; platelet aggregation inhibitors; prasugrel hydrochloride

Indexed keywords

CLOPIDOGREL; PRASUGREL; TICAGRELOR; ADENOSINE; TICLOPIDINE; TROPONIN;

ACUTE CORONARY SYNDROME; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NOTE; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBUS; ANALOGS AND DERIVATIVES; BLOOD; FEMALE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE CARE; PROCEDURES;

ACUTE CORONARY SYNDROME; ADENOSINE; FEMALE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE CARE; TICLOPIDINE; TROPONIN;

EID: 84958780814     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.11.043     Document Type: Editorial

References (23)

1. M. Roffi, C. Patrono, J.P. Collet, and et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur Heart J 37 2016 267 315
2. E.A. Amsterdam, N.K. Wenger, R.G. Brindis, and et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 64 2014 e139 e228
3. 12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis J Am Coll Cardiol 56 2010 1542 1551
4. L. Wallentin, D. Lindholm, A. Siegbahn, and et al. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial Circulation 129 2014 293 303
5. Task Force Members G. Montalescot, U. Sechtem, and et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Eur Heart J 34 2013 2949 3003
6. 12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention Circ J 78 2014 2926 2934
7. 12 inhibitors Circ J 78 2014 2840 2842
8. K.N. Garratt, W.D. Weaver, R.G. Jenkins, and et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement Circulation 131 2015 62 73
9. 12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial Circulation 111 2005 3366 3373
10. D. Trenk, G.W. Stone, M. Gawaz, and et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study J Am Coll Cardiol 59 2012 2159 2164
11. J.P. Collet, J. Silvain, and G. Montalescot Long-term secondary prevention after high-risk stenting: a good drug for a bad stent Circulation 131 2015 13 16
12. G. Parodi, B. Bellandi, R. Valenti, and et al. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study Am Heart J 167 2014 909 914
13. M.P. Bonaca, D.L. Bhatt, M. Cohen, and et al. Long-term use of ticagrelor in patients with prior myocardial infarction N Engl J Med 372 2015 1791 1800
14. D.J. Angiolillo, F. Franchi, R. Waksman, and et al. Effects of ticagrelor versus clopidogrel in troponin-negative patients with low-risk ACS undergoing ad hoc PCI J Am Coll Cardiol 67 2016 603 613
15. A. Bellemain-Appaix, S.A. O'Connor, J. Silvain, and et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis JAMA 308 2012 2507 2516
16. A. Bellemain-Appaix, M. Kerneis, S.A. O'Connor, et al. for the ACTION Study Group Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis Br Med J 349 2014 g6269
17. G. Montalescot, L. Bolognese, D. Dudek, and et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes N Engl J Med 369 2013 999 1010
18. J. Silvain, R. Storey, G. Cayla, and et al. Impact of morphine administration on ticagrelor-induced platelet inhibition in ST-elevation myocardial infarction patients treated by primary PCI: results from the PRIVATE-ATLANTIC study (abstr) J Am Coll Cardiol 65 2015 A51
19. G. Montalescot, A.W. van 't Hof, F. Lapostolle, and et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction N Engl J Med 371 2014 1016 1027
20. D.L. Bhatt, G.W. Stone, K.W. Mahaffey, and et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313
21. G. Montalescot Effect of prehospital ticagrelor in STEMI patients in the first 24 hours after primary PCI: the ATLANTIC-H24 analysis J Am Coll Cardiol Intv 2016 In press
22. T. Omland, J.A. de Lemos, M.S. Sabatine, and et al. A sensitive cardiac troponin T assay in stable coronary artery disease N Engl J Med 361 2009 2538 2547
23. G. Parodi, I. Xanthopoulou, B. Bellandi, and et al. Ticagrelor crushed tablets in STEMI patients: the MOJITO study J Am Coll Cardiol 65 2015 511 512